Logo
Whalesbook
HomeNewsCorporate NewsPremiumStocks
HomeNewsCorporate NewsPremiumStocks

Vivanza Biosciences Ltd

₹ 2.292.23%
14 Jan – close price
🔗vivanzabiosciences.com•BSE: 530057•NSE:
Market Cap₹ 9.16 Cr.
Current Price₹ 2.29
High / Low₹ 3.45
Stock P/Enull
Book Value₹ 1.12
Dividend Yield0.00 %
ROCE-3.76 %
ROE-16.0 %
Face Value₹ 1.00
Sales₹ 62.5 Cr.
OPM-0.30 %
Mar Cap₹ 9.16 Cr.

ABOUT

Incorporated in 2016, Vivanza Biosciences Ltd is in the business of providing medicines and healthcare solutions[1]

KEY POINTS

Business Overview:[1]VBL's core areas include research and development, manufacturing, and distribution of a wide range of pharmaceutical products

Also present in buckets:
Aggressive Growth TriggersExcellent ResultsAsset Base ExpansionCapacity Expansion And ProductsRed Flags And Poor Performance

Peer Comparision

S.No.NameCurrent Price (Rs.)Price to EarningMarket Capitalization (Rs.Cr.)Dividend yield (%)Net Profit latest quarter (Rs.Cr.)YOY Quarterly profit growth (%)Sales latest quarter (Rs.Cr.)YOY Quarterly sales growth (%)Return on capital employed (%)Sales (Rs.Cr.)OPM (%)Profit after tax (Rs.Cr.)Profit after tax latest quarter (Rs.Cr.)Price to book valueReturn on assets (%)Debt to equity
1.Sun Pharma.Inds.1700.7035.35408054.900.943124.952.5614478.318.9320.2154964.0130.1211543.963117.955.2412.970.07
2.Divi's Lab.6355.5067.89168718.560.47689.0035.102715.0016.1220.4410029.0032.372485.00689.0010.9513.530.01
3.Torrent Pharma.4003.7062.54135503.400.80591.0032.493302.0014.3027.0512248.0032.602166.53600.1716.0413.260.33
4.Cipla1434.5021.30115874.780.911353.373.737589.447.6422.7228349.5725.405441.141351.173.5214.720.01
5.Lupin2195.9023.19100308.450.551484.8373.347047.5124.2321.3024750.6927.254324.631477.925.1112.410.32
6.Dr Reddy's Labs1186.5017.1699028.890.671336.807.288828.309.8322.6934310.0024.645772.201347.102.7512.950.16
7.Mankind Pharma2244.4052.9992649.970.04520.18-22.003697.1620.7715.9813545.6724.121748.55511.516.068.890.55
8.Vivanza Biosci.2.29–9.160.000.464500.0053.733300.63-3.7662.48-0.30-0.450.462.04-4.551.62
–Median: 149 Co.394.529.561738.640.1213.4911.71161.7610.5814.89591.7315.9345.2613.963.148.560.22

Quarterly Results

Standalone figures in ₹ crores

Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Sales
1.044.806.024.883.873.372.300.431.580.760.177.8253.73
Expenses
1.034.285.984.453.623.112.440.111.480.641.077.7453.22
Operating Profit
0.010.520.040.430.250.26-0.140.320.100.12-0.900.080.51
Other Income
0.240.010.120.010.050.02-0.030.000.000.010.020.020.01
Profit before tax
0.150.420.060.330.190.18-0.270.230.010.04-0.960.020.47
Tax %
0.00%0.00%200.00%0.00%0.00%0.00%40.74%0.00%0.00%0.00%0.00%0.00%0.00%
Net Profit
0.150.42-0.050.330.190.18-0.380.230.010.04-0.970.020.46
EPS in Rs
0.040.10-0.010.080.050.04-0.100.060.000.01-0.240.000.12

Profit & Loss

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales
0.000.000.003.466.442.229.379.229.1414.2114.412.9162.48
Expenses
0.050.050.063.635.802.259.669.099.0713.4813.603.2762.67
Operating Profit
-0.05-0.05-0.06-0.170.64-0.03-0.290.130.070.730.81-0.36-0.19
Other Income
0.000.000.000.050.000.000.530.500.830.390.050.030.06
Interest
0.000.000.000.040.370.420.440.470.430.430.420.350.30
Depreciation
0.000.000.000.000.000.000.000.010.010.000.010.010.00
Profit before tax
-0.05-0.05-0.06-0.160.27-0.45-0.200.150.460.690.43-0.69-0.43
Net Profit
-0.05-0.05-0.06-0.160.24-0.45-0.200.100.460.570.32-0.70-0.45
EPS in Rs
-0.01-0.01-0.32-0.040.06-0.11-0.050.020.120.140.08-0.18-0.11
Dividend Payout %
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%–

Compounded Sales Growth

10 Years:%
5 Years:-21%
3 Years:-32%
TTM:714%

Compounded Profit Growth

10 Years:%
5 Years:%
3 Years:%
TTM:-1225%

Stock Price CAGR

10 Years:-11%
5 Years:-30%
3 Years:-48%
1 Year:-33%

Return on Equity

10 Years:0%
5 Years:4%
3 Years:1%
Last Year:-16%

Balance Sheet

Standalone figures in ₹ crores

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital
3.763.760.194.004.004.004.004.004.004.004.004.004.00
Reserves
-3.54-3.59-0.16-0.32-0.08-0.53-0.73-0.63-0.170.400.720.020.50
Borrowings
0.390.480.500.530.770.900.180.184.426.563.266.097.29
Other Liabilities
0.080.090.112.724.966.468.834.385.969.488.893.8033.34
Total Liabilities
0.690.740.646.939.6510.8312.287.9314.2120.4416.8713.9145.13
Fixed Assets
0.000.000.000.000.000.000.000.010.000.000.030.020.01
Gross Block
0.000.000.000.000.000.000.000.020.020.020.060.07–
Accumulated Depreciation
0.000.000.000.000.000.000.000.010.020.020.030.05–
CWIP
0.000.000.000.000.000.000.000.000.000.000.000.000.00
Investments
0.000.000.001.911.911.911.911.911.911.911.911.911.91
Other Assets
0.690.740.645.027.748.9210.376.0112.3018.5314.9311.9843.21
Total Assets
0.690.740.646.939.6510.8312.287.9314.2120.4416.8713.9145.13

Cash Flows

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity
-0.03-0.04-0.05-1.98-0.161.372.80-3.08-0.680.161.80-2.47
Cash from Investing Activity
0.000.000.001.900.000.000.00-0.020.000.00-0.04-0.01
Cash from Financing Activity
0.030.090.02-2.28-0.53-1.38-2.582.800.65-0.08-1.772.44
Net Cash Flow
0.000.05-0.02-2.36-0.69-0.010.22-0.30-0.030.09-0.01-0.04

Ratios

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days
–––266.89287.35910.86249.70241.88293.52312.86262.67926.92
Inventory Days
–––215.20150.49352.1033.9417.0495.9845.3450.62255.36
Days Payable
–––304.36319.461,059.97325.07164.40235.87243.90231.43446.88
Cash Conversion Cycle
–––177.72118.38202.98-41.4394.52153.63114.3081.86735.40
Working Capital Days
–––369.22251.08656.01139.07156.3751.9145.9872.70277.20
ROCE %
-8.06%-7.94%-10.17%-5.06%14.38%-0.66%6.14%17.71%15.08%11.66%8.98%-3.76%

Shareholding Pattern

Numbers in percentages

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Promoters
47.80%47.80%47.80%47.29%44.90%43.24%40.05%39.86%20.02%20.02%20.02%20.02%
FIIs
––––––––––––
DIIs
––––––––––––
Public
52.20%52.20%52.20%52.70%55.10%56.75%59.95%60.13%79.98%79.98%79.98%79.98%

* The classifications might have changed from Sep'2022 onwards.ℹ️

BSE Announcements AI Summary

Direct from BSE filings, auto-summarised

Vivanza Biosciences Exempt from Annual Secretarial Compliance Report for FY26

15th April 2026, 5:42 pm

Vivanza Biosciences Confirms No New Fund Raising, Deviation Statement Not Applicable

14th April 2026, 9:48 pm

Vivanza Biosciences: RTA Confirms SEBI Compliance, No Share Dematerialization for Quarter Ended March 2026

7th April 2026, 7:27 pm

Vivanza Biosciences Closes Trading Window Ahead of Q4/FY26 Results

23rd March 2026, 9:02 pm

Vivanza Biosciences Director Resigns Due to Personal Reasons

17th March 2026, 8:59 pm

Published by Other Websites

External media mentions & references

Indian Market Cap Soars Past Rs 473 Lakh Crore! Sensex, Nifty Edge Higher - Don't Miss This Crucial Update!

13th November 2025, 4:49 pm

Vivanza Biosciences Closes Trading Window Ahead of Q4 FY26 Results

News Articles

Editorial & research coverage

Indian Market Cap Soars Past Rs 473 Lakh Crore! Sensex, Nifty Edge Higher - Don't Miss This Crucial Update!
Indian Market Cap Soars Past Rs 473 Lakh Crore! Sensex, Nifty Edge Higher - Don't Miss This Crucial Update!

13th November 2025, 4:49 pm

Documents

Announcements

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

2 Jan - Confirmation Certificate Under regulation 74(5) of SEBI (Depositories and participants) Regulations, 2018 received from Purva Sharegistry (I) Private Limited, Registrar and Share Transfer Agent (RTA) …

Closure of Trading Window
Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association

18 Dec - Dec 18, 2025: Shareholders approved adding MOA sub-clause to manufacture plastic packaging materials, subject to approvals.

Shareholder Meeting / Postal Ballot-Scrutinizer"s Report

17 Dec - Special resolution to alter MOA passed Dec 16, 2025; 5,106,561 for (99.90%), 4,978 against.

Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot

Annual Reports

Financial Year 2025

(from bse)

Financial Year 2024

(from bse)

Financial Year 2023

(from bse)

Financial Year 2022

(from bse)

Financial Year 2021

(from bse)

Financial Year 2020

(from bse)

Financial Year 2019

(from bse)

Financial Year 2018

(from bse)

Financial Year 2017

(from bse)

Financial Year 2016

(from bse)

Financial Year 2015

(from bse)

Financial Year 2014

(from bse)

Financial Year 2013

(from bse)

Financial Year 2012

(from bse)

Financial Year 2011

(from bse)

Credit Ratings

No credit ratings.

Concalls

No concalls.

Stock Analysis

Description

Vivanza Biosciences Limited operates in the pharmaceutical and healthcare solutions sector, focusing on research, development, manufacturing, and distribution of pharmaceutical products. The company is currently undertaking significant diversification efforts into new business verticals.

Key Growth Triggers

  1. Diversification into plastic packaging (manufacturing, trading of films, bags).
  2. Expansion into agro-products, renewable energy, IT, and real estate, as approved by shareholders.
  3. Strategic shift to explore new market segments and revenue streams following a period of financial challenges.

Order Book

Currently no data available for Order Book.

Key Red Flags

  1. Significant historical performance downturn in FY24-25, marked by steep revenue decline and net losses.
  2. Promoter holding has substantially decreased over recent periods.
  3. Past financial statements indicated challenges such as high debt-to-equity ratio and negative operating cash flows.

Key Dates To Watch

  1. Q3 FY26 financial results are expected in February 2026, which will provide further insight into ongoing recovery and diversification impact.

Corporate Announcements

15th Apr 26
Impact Rating: 5
Vivanza Biosciences will not file its Annual Secretarial Compliance Report for FY26, as its paid-up capital (₹4 cr) and net worth (₹4.02 cr) are below SEBI's exemption limits.
14th Apr 26
Impact Rating: 3
Vivanza Biosciences Limited has confirmed to BSE that it has not raised any further funds through Public Issue, Rights Issue, or Preferential Issue. Consequently, the Statement of Deviation or Variation, as per SEBI regulations, is not applicable to the company.
7th Apr 26
Impact Rating: 3
Vivanza Biosciences has filed its SEBI Regulation 74(5) compliance certificate for the quarter ended March 31, 2026. The RTA confirmed correct processing of dematerialization requests, with a key point being that no shares were dematerialized during this period.
23rd Mar 26
Impact Rating: 6
Vivanza Biosciences will close its trading window for Promoters, Directors, KMPs, and connected persons from April 1, 2026. This closure will last until 48 hours after the declaration of financial results for Q4 and FY26.
17th Mar 26
Impact Rating: 5
Vivanza Biosciences Limited has accepted the resignation of Mr. Hemant Amrish Parikh as Non-Executive Director from March 17, 2026, due to personal reasons. The company confirmed no other material reasons for his departure.